Evidence map›Paper›PMID 34476764›Full record

ArticleDrug delivery and translational research2022

Appraisal of fluoroquinolone-loaded carubinose-linked hybrid nanoparticles for glycotargeting to alveolar macrophages.

Priyanka Maurya, Ravi Saklani, Samipta Singh, Raquibun Nisha, Ravi Raj Pal, Nidhi Mishra, Priya Singh, Abhiram Kumar, Manish K Chourasia, Shubhini A Saraf

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Priyanka MauryaDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Ravi SaklaniDepartment of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
Samipta SinghDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Raquibun NishaDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Ravi Raj PalDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Nidhi MishraDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Priya SinghDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India.
Abhiram KumarDepartment of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
Manish K ChourasiaDepartment of Pharmaceutics and Pharmacokinetics, CSIR-Central Drug Research Institute, Sector 10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, India.
Shubhini A SarafDepartment of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University, ) Vidya Vihar, Raebareli Road, Lucknow, 226025, India. shubhini.saraf@gmail.com.ORCID 0000-0002-4180-0931
Babasaheb Bhimrao Ambedkar University · INCentral Drug Research Institute · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a curious case in Alveolar macrophages (AM), the frontline defence recruits that contain the spread of all intruding bacteria. In response to Mycobacterium tuberculosis (M.tb), AM either contain the spread or are modulated by M.tb to create a region for their replication. The M.tb containing granulomas so formed are organised structures with confined boundaries. The limited availability of drugs inside AM aid drug tolerance and poor therapeutic outcomes in diseases like tuberculosis. The present work proves the glycotargeting efficiency of levofloxacin (LVF) to AM. The optimised formulation developed displayed good safety with 2% hemolysis and a viability of 61.14% on J774A.1 cells. The physicochemical characterisations such as Fourier-transform infrared spectroscopy (FTIR), X-ray diffraction (XRD), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) proved that carubinose linkage was accomplished and LVF is entrapped inside carubinose-linked hybrid formulation (CHF) and hybrid formulation (HF) in amorphous form. The transmission electron microscopy (TEM) images revealed a core-shell structure of HF. The particle size of 471.5 nm estimated through dynamic light scattering (DLS) is enough to achieve active and passive targeting to AM. The nanoparticle tracking analysis (NTA) data revealed that the diluted samples were free from aggregates. Fluorescence-activated cell sorting (FACS) data exhibited excellent uptake via CHF (15 times) and HF(3 times) with reference to plain fluorescein isothiocyanate (FITC). The pharmacokinetic studies revealed that CHF and HF release the entrapped moiety LVF in a controlled manner over 72 h. The stability studies indicated that the modified formulation remains stable over 6 months at 5 ± 3℃. Hence, hybrid systems can be efficiently modified via carubinose to target AM via the parenteral route.

Indexed as

FluoroquinolonesNanoparticlesCalorimetry, Differential ScanningMacrophages, AlveolarParticle SizeSpectroscopy, Fourier Transform InfraredX-Ray DiffractionFluoroquinolonesCarubinoseFlow cytometryHybrid nanoparticlesMacrophage targetingNTA analysisThermal analysis

Identifiers

PMID34476764
OpenAlexW3196796671

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.